Evidence map›Paper›PMID 18406562›Full record

ArticlePatient education and counseling2008

How much time does it take to prescribe a new medication?

Derjung M Tarn, Debora A Paterniti, Richard L Kravitz, John Heritage, Honghu Liu, Sue Kim, Neil S Wenger

Abstract read
In one paragraph

Article in Patient education and counseling, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Article
  3. Emotional barriers and facilitators of deprescribing for older adults with cancer and polypharmacy: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Integrating pharmacogenetic testing into primary care.Expert review of precision medicine and drug development · 2017
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2013
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Derjung M TarnDepartment of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA. dtarn@mednet.ucla.edu
Debora A Paterniti
Richard L Kravitz
John Heritage
Honghu Liu
Sue Kim
Neil S Wenger

Funding

MENTORED CLINICAL SCIENTIST DEVELOPMENT PROGRAMK12AG001004 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REUBEN, DAVID B. · 2000 to 2009
$4.3M
Improving Care for Comorbid Physical and Mental IllnessK24MH072756 · NIMH · UNIVERSITY OF CALIFORNIA DAVIS · PI KRAVITZ, RICHARD L · 2005 to 2009
$643k
NIA NIH HHS 5 K12 AG 001004NIA NIH HHS K12 AG001004NIMH NIH HHS 1 K24 MH 072756-01NIMH NIH HHS K24 MH072756
6 · The paper itself

Abstract

objectiveTo measure the length of time spent discussing all aspects of new prescriptions and guideline-recommended aspects of counseling, and to evaluate factors associated with duration of discussion.

methodsWe analyzed tape recordings in which 181 patients received 234 new medication prescriptions from 16 family physicians, 18 internists, and 11 cardiologists in 2 healthcare systems in Sacramento, California between January and November 1999.

resultsOf the mean total visit time of 15.9min (S.D.=434s), a mean of 26s (S.D.=28s) was allocated to guideline-recommended components and a mean of 23s (S.D.=25s) was allocated to discussion of all other aspects of new prescription medications. The majority of time spent discussing individual new prescriptions was dedicated to: medication purpose or justification, directions and duration of use, and side effects. On average, more complete discussion of these components was associated with more time. More time was spent talking about guideline-recommended information if patients were in better health, if there was a third party in the room, and if the medication belonged to a psychiatric, compared to an ear, nose, throat medication class. Less time was spent discussing over-the-counter (OTC) medications and those prescribed to patients with a previous visit to the physician.

conclusionHigher quality information transmission between physicians and patients about new medications requires more time, and may be difficult to achieve in short office visits. PRACTICE IMPLICATIONS: Time-compressed office visits may need to be redesigned to promote improved provider-patient communication about new medications.

Indexed as

CommunicationPhysician-Patient RelationsAdultCaliforniaCardiologyCounselingDrug PrescriptionsFamily PracticeFemaleHealth Services ResearchHumansInternal MedicineLinear ModelsMaleMiddle AgedMultivariate Analysis

Identifiers

PMID18406562
PMCPMC2582184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.